[{"address1": "665 Stockton Drive", "address2": "Suite 300", "city": "Exton", "state": "PA", "zip": "19341", "country": "United States", "phone": "610 321 3700", "website": "https://immunome.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Dr. Clay B. Siegall Ph.D.", "age": 62, "title": "President, CEO & Chairman", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott K. Dessain M.D., Ph.D.", "title": "Co-founder & Chairman of the Scientific Advisory Board", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1704067200, "maxAge": 86400, "priceHint": 2, "previousClose": 11.81, "open": 12.06, "dayLow": 11.5, "dayHigh": 12.55, "regularMarketPreviousClose": 11.81, "regularMarketOpen": 12.06, "regularMarketDayLow": 11.5, "regularMarketDayHigh": 12.55, "payoutRatio": 0.0, "beta": 1.536, "forwardPE": -11.425743, "volume": 461296, "regularMarketVolume": 461296, "averageVolume": 155737, "averageVolume10days": 309400, "averageDailyVolume10Day": 309400, "bid": 0.0, "ask": 0.0, "bidSize": 1100, "askSize": 900, "marketCap": 505076960, "fiftyTwoWeekLow": 3.75, "fiftyTwoWeekHigh": 12.55, "priceToSalesTrailing12Months": 49.556217, "fiftyDayAverage": 8.4722, "twoHundredDayAverage": 7.00115, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 402811424, "profitMargins": -2.15443, "floatShares": 24668368, "sharesOutstanding": 42729800, "sharesShort": 678116, "sharesShortPriorMonth": 428151, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.0159, "heldPercentInsiders": 0.25258, "heldPercentInstitutions": 0.2374, "shortRatio": 3.55, "shortPercentOfFloat": 0.0165, "impliedSharesOutstanding": 43767500, "bookValue": 0.498, "priceToBook": 23.172691, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -21958000, "trailingEps": -1.76, "forwardEps": -1.01, "enterpriseToRevenue": 39.522, "enterpriseToEbitda": -18.093, "52WeekChange": 1.5021186, "SandP52WeekChange": 0.20374417, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMNM", "underlyingSymbol": "IMNM", "shortName": "Immunome, Inc.", "longName": "Immunome, Inc.", "firstTradeDateEpochUtc": 1601645400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c2147e86-3bc9-3a00-bf6a-53fc4499717d", "messageBoardId": "finmb_108518404", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.54, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 90641000, "totalCashPerShare": 2.121, "ebitda": -22263000, "totalDebt": 350000, "quickRatio": 3.922, "currentRatio": 3.955, "totalRevenue": 10192000, "debtToEquity": 5.76, "revenuePerShare": 0.837, "returnOnAssets": -0.22900999, "returnOnEquity": -1.5060401, "freeCashflow": 8027000, "operatingCashflow": 3208000, "grossMargins": 1.5467, "ebitdaMargins": -2.18436, "operatingMargins": -1.29958, "financialCurrency": "USD", "trailingPegRatio": null}]